Research and Markets

Research and Markets

August 01, 2014 10:00 ET

Global Isothermal Nucleic Acid Amplification Technology (INAAT) (Infectious Diseases, Blood Screening, Research) Market - Forecast to 2018

DUBLIN, IRELAND--(Marketwired - Aug. 1, 2014) - Research and Markets ( has announced the addition of the "Isothermal Nucleic Acid Amplification Technology (INAAT) (Infectious Diseases, Blood Screening, Research) Market - Forecast to 2018" report to their offering.

The isothermal nucleic acid amplification technology (INAAT) market is poised to reach $1,651 million by 2018 at a CAGR of 13.5% during the forecast period. Despite the dominance of polymerase chain reaction (PCR) technology, INAAT is expected to seize a considerable market space in the global market since it enhances the quality of point-of-care testing using miniature DNA diagnostics.

Major driving factors of the global market includes increasing prevalence of infectious disease and cancer, promise for less expensive and better throughput in gene amplification using INAAT, and advent of novel technologies such as Loop-Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA) and Helicase Dependent Amplification (HDA). However, inadequate automation and portability, and high dominance of PCR technology restrict the adoption of isothermal amplification technology globally.

Reagent segment held the maximum share of 70% of the global market in 2013; the segment is expected to grow at 14.7% CAGR due to increasing consumption of reagents in the detection of chronic diseases and genetic disorders. Future scope of market development lies in less expensive and portable POCT device as well as real time Chip based Nucleic Acid Testing (NAT) for SNP genotyping and cancer. Currently, difficulties in developing lab-on-chip due to lack of multidisciplinary approach, and high entry barrier in PCR dominated emerging nations restrict the market momentum in the developing countries.

Infectious disease was found to be the highest revenue generating segment (57.2%) of the global isothermal nucleic acid amplification technology market in 2013; it is expected to grow at a double digit growth during the forecast period. It is primarily attributed to high incidence rate of various infectious diseases such as HIV and hepatitis A & B, and increasing importance of INAAT in infection detection globally. Adoption of INAAT in blood screening application is also expected to grow as it ensures the quality of donated blood through its early prognosis of pathogen; whereas, cancer research, whole genome amplification, mutation, SNP detection and expression analysis are expected to drive the INAAT research application market.

Amongst different end-users, hospital segment accounts for the maximum share of the global end-user market in 2013. However, INAAT adoption in reference laboratories is expected to grow significantly due to increasing awareness of isothermal technology in different complex molecular testing.

North America contributed the largest market share of about 44% in 2013. On the other hand, increasing prevalence of infectious diseases and significant adoption of novel technologies are expected to drive the Asian market in the coming years. India, China, South Africa, Singapore, and Middle East were identified as the major focus areas amongst different emerging nations.

The notable players in the global isothermal nucleic acid amplification technology market include Alere, Inc. (U.S.), Becton, Dickinson & Company (U.S.), BioHelix (U.S.), bioMerieux (France), Hologic Gene-Probe (U.S.), and QIAGEN (The Netherlands).

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Technology Landscape Analysis

4 Technology Investment Potential

5 Market Landscape Analysis

6 Product Market

7 Applications Market

8 End-User Market

9 Geographic Analysis

10 Competitive Landscape

11 Company Profiles

Companies Mentioned:

  • Alere
  • Becton, Dickinson and Company (Bd)
  • Biohelix
  • Biomerieux
  • Eiken Chemical Co., Ltd.
  • Hologic Gen-Probe
  • Lucigen
  • Meridian Bioscience, Inc.
  • New England Biolabs
  • Novartis Diagnostics
  • Nugen
  • Qiagen
  • Ustar Biotechnologies

For more information visit

Sector: Advanced Technology

Contact Information

  • Research and Markets
    Laura Wood, Senior Manager
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900

    Research and Markets
    U.S. Fax: 646-607-1907
    Fax (outside U.S.): +353-1-481-1716